文献速递治疗药物监测与药物基因组学特殊人群用药

CYP3A5基因变异在肾移植受者中的流行率及其对他克莫司剂量的影响

Prevalence of CYP3A5 Genomic Variances and Their Impact on Tacrolimus Dosing Requirements among Kidney Transplant Recipients in Eastern North Carolina.
PubMed 文献 · Pharmacotherapy · 2017-07-27

一项单中心回顾性队列研究纳入162例肾移植成人受者,评估CYP3A5基因变异流行率及其对他克莫司(TAC)剂量的影响。CYP3A5*1表达组达到首个治疗谷浓度所需TAC总日剂量显著高于非表达组(12 vs 8 mg/day,p≤0.001),且按体重计高50%(0.15 vs 0.1 mg/kg/day,p≤0.0005)。CYP3A5*1组以非裔美国人为主(93%,p≤0.0005)。

要点

  • CYP3A5*1表达者达到首个治疗谷浓度所需TAC总日剂量显著高于非表达者。
  • CYP3A5*1表达者TAC总日剂量按体重计比非表达者高50%。
  • CYP3A5*1变异在非裔美国肾移植受者中高发,提示该人群可能需要更高TAC剂量。

核心结论

  • CYP3A5*1变异在非裔美国肾移植受者中高发,且该变异表达者平均需要更高TAC剂量才能达到理想药物浓度。

研究设计与样本

  • 单中心回顾性队列研究,纳入2013年3月1日至2015年2月28日期间接受肾移植并口服TAC作为维持免疫抑制的162例成人受者。
  • 85例为CYP3A5*1变异表达组,77例为其他CYP3A5变异非表达组,所有患者随访移植后1年。

主要发现

  • CYP3A5*1表达组与非表达组在性别、平均年龄和平均体重上无显著差异。
  • CYP3A5*1组以非裔美国人为主(93%,p≤0.0005)。
  • CYP3A5*1表达组达到首个治疗TAC谷浓度时的平均TAC总日剂量显著高于非表达组(12 vs 8 mg/day,p≤0.001)。
  • CYP3A5*1表达组按体重计的平均TAC总日剂量比非表达组高50%(0.15 vs 0.1 mg/kg/day,p≤0.0005)。
  • 主要基因型变异为CYP3A5*3/*3(33%)、CYP3A5*1/*3(20%)和CYP3A5*1/*1(19%)。

关键数值与推荐

  • CYP3A5*1表达组达到首个治疗谷浓度所需TAC总日剂量为12 mg/day,非表达组为8 mg/day(p≤0.001)。
  • CYP3A5*1表达组按体重计TAC总日剂量为0.15 mg/kg/day,非表达组为0.1 mg/kg/day(p≤0.0005)。
  • CYP3A5*1组中非裔美国人占93%(p≤0.0005)。
  • 主要基因型频率:CYP3A5*3/*3为33%,CYP3A5*1/*3为20%,CYP3A5*1/*1为19%。

临床怎么用

  • 对于携带CYP3A5*1变异的肾移植受者,尤其是非裔美国人,可考虑更积极地调整TAC剂量以达到目标谷浓度。
  • CYP3A5基因分型有助于识别可能需要更高TAC剂量的患者,以平衡免疫抑制不足和毒性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To assess the prevalence of CYP3A5 genomic variances and their impact on tacrolimus (TAC) dosing requirements among kidney transplant recipients in eastern North Carolina, we conducted a single-center retrospective cohort study at a large tertiary care medical center. A total of 162 adults who received a kidney transplant between March 1, 2013, and February 28, 2015, and received oral TAC as part of their maintenance immunosuppression were enrolled. Of these patients, 85 patients expressed a genotype with a CYP3A5*1 variant (CYP3A5*1 group), and 77 patients expressed genotypes with other CYP3A5 variants (nonexpressor group). All patients were followed for 1 year posttransplantation. The primary end point was the TAC total daily dose (TDD) required to achieve the first therapeutic trough level based on the presence or absence of the CYP3A5*1 variant. The prevalence of different CYP3A5 variants across race/ethnicities in the study cohort was determined by CYP3A5 genotyping for each patient. The CYP3A5*1 and nonexpressor groups did not differ significantly with respect to sex, mean age, or mean weight. The CYP3A5*1 group was largely African American (93%, p≤0.0005) compared with other race/ethnicities. Among the CYP3A5*1 expressors compared with nonexpressors, the mean TAC TDD in milligrams at the first therapeutic TAC level was significantly higher (12 vs 8 mg/day, p≤0.001). Similarly, the mean TAC TDD in milligrams/kilogram was 50% greater among CYP3A5*1 expressors (0.15 vs 0.1 mg/kg/day, p≤0.0005). The predominant genotypic variants were CYP3A5*3/*3 (33%), CYP3A5*1/*3 (20%), and CYP3A5*1/*1 (19%). This study illustrates the prevalence of the CYP3A5*1 variant among African-American kidney transplant recipients and the effect of this gene expression on the TAC TDD. Patients with the CYP3A5*1 variant require higher TAC doses, on average, to achieve desirable drug levels. In addition, this study provides transplant clinicians with insight and support to dose TAC more aggressively in African-American kidney transplant recipients who may be at higher risk for both toxicities as well as poor clinical outcomes related to inadequate immunosuppression.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Maldonado AQ, Asempa T, Hudson S, et al. Prevalence of CYP3A5 Genomic Variances and Their Impact on Tacrolimus Dosing Requirements among Kidney Transplant Recipients in Eastern North Carolina. Pharmacotherapy. 2017. PMID: 28605053. doi:10.1002/phar.1970

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。